July 27, 2012 at 06:50 AM EDT
Transgene and Tasly JV Starts Operations with Four Transgene Molecules
The JV established by France’s Transgene and Tasly Pharma of China announced that Transgene is contributing China rights to four biotech immunotherapeutic candidates to the JV. The JV will be capitalized with $3.2 million from Transgene and $6.6 million from Tasly. The value of Transgene’s drug IP evens its investment in the 50:50 partnership with Tasly’s. Transgene develops immunotherapeutic products aimed at cancer and infectious diseases. More details.... Stock Symbols: (Euronext: TNG) (SHA: 600535) Share this with colleagues: var switchTo5x=true; stLight.options({publisher:'d7871f5b-67bc-4d30-b66f-1465d0b97213'});  
Related Stocks:
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here